Pharmaceuticals Trio Draw Buy Ratings Ahead of 2026 Catalysts
A trio of small-cap biotechs—X4 Pharmaceuticals, Immuneering, and Tango Therapeutics—are attracting new and renewed a...
Building wealth without taking high risks is achievable with the right strategies. Explore options that prioritize safety and growth.
27,007 articlesA trio of small-cap biotechs—X4 Pharmaceuticals, Immuneering, and Tango Therapeutics—are attracting new and renewed a...
Public sentiment is sharply divided over U.S. action against Iran, with most polls showing more oppose than support. ...
Investors flooded crypto funds with $858M in inflows as lawmakers push a clarity-focused framework for stablecoins. T...
A memory-focused rally has vaulted a mid-cap equipment maker by about 90% in 2.5 months, shifting attention away from...
Salesforce just announced a massive buyback, but does that mean now is the time to buy CRM stock? This guide breaks d...
A surprising rally in small-cap value equities challenges the usual price-pressures from inflation and higher rates. ...
JPMorgan Chase moves to a two-person succession test by naming Doug Petno and Troy Rohrbaugh co-presidents, laying th...
A disciplined investment approach blends steady dividend payers with selective high-yield assets to produce durable i...
Geopolitical drama around the Strait of Hormuz could ripple through markets and raise inflation. This guide explains ...
Starting to invest can feel overwhelming. This guide helps you understand risk tolerance and build your first portfol...
RE/MAX brokers are turning to repeatable systems over lofty goals to push growth amid market shifts, with panels at R...
A growing gap between what Social Security takes in and what it pays out could hit retirees hard. Learn who’s at risk...